150 L of 0.2 mol/L pH 7.8 phosphate buffer, 50 L of proxy matrix, and 10 L of 0.001 mol/L N-Hcy-Lys were mixed with 5 L of a mixture, prepared by mixing 0.2 mol/L BCPB solution and 0.25 mol/L TCEP solution in volume ratio 1:1
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Studies on rodents have shown GLP-1 receptor agonists can have antidepressant effects, but only with long-term use
The review of diabetic studies : RDS, 11(3-4), 202230
At 4 g, the daily maximal dose recommended by the FDA, there is also no difference between the sexes (simulations not shown)
